Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
Boeing Reaches Tentative Settlement With Canadian Victim’s Family in 737 MAX Crash Lawsuits 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
Saks Global Files for Bankruptcy Protection Amid Mounting Luxury Retail Pressures 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
U.S. Lawmakers Raise Alarm Over Trump Approval of Nvidia AI Chip Sales to China 
LEIDEN, the Netherlands, April 10, 2017 -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that the Annual General Meeting of Shareholders will be held on Wednesday, May 10, 2017 at 15:00 CET, at the offices of Allen & Overy at Apollolaan 15, 1077 AB Amsterdam, the Netherlands.
All relevant documents and information for the meeting, including the notice and agenda, are or will be made available in the ‘Investor Relations’ section of ProQR’s website (www.proqr.com) under ‘Financial Information’. The documents will also be made available on the SEC's website at www.sec.gov.
A live webcast of the event will be accessible in the ‘Investor Relations’ section of ProQR’s website under ‘Events and Presentations’.
About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases such as cystic fibrosis, Leber’s congenital amaurosis Type 10 and dystrophic epidermolysis bullosa. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
*Since 2012*
Contact:
Smital Shah
Chief Financial Officer
T: +1 415 231 6431
[email protected]
